AstraZeneca, Ranbaxy Settle Nexium Patent Dispute
Under the settlement agreement, Ranbaxy has agreed that all six patents asserted by AstraZeneca are valid and enforceable. Ranbaxy also concedes that four of the patents would be infringed through the unlicensed sale of the generic product Ranbaxy had proposed.
With a license from AstraZeneca, Ranbaxy's 180-day exclusivity period as the distributor of generic Nexium will begin on May 27, 2014, the day U.S....
To view the full article, register now.